Virtual Library
Start Your Search
M. Suzuki
Author of
-
+
MA11 - Novel Approaches in SCLC and Neuroendocrine Tumors (ID 391)
- Event: WCLC 2016
- Type: Mini Oral Session
- Track: SCLC/Neuroendocrine Tumors
- Presentations: 1
- Moderators:P. Lara, A. Mohn-Staudner
- Coordinates: 12/06/2016, 14:20 - 15:50, Strauss 3
-
+
MA11.03 - INSM1 is a Novel Biomarker and a Crucial Regulator of the Neuroendocrine Differentiation Pathway in Neuroendocrine Tumours of the Lung (ID 5205)
14:20 - 15:50 | Author(s): M. Suzuki
- Abstract
- Presentation
Background:
Insulinoma-associated protein 1 (INSM1) is expressed predominantly in embryonic developing neuroendocrine (NE) tissues, and the expression is significantly reduced/restricted in adult tissues. We previously revealed that INSM1 is expressed exclusively in small cell lung cancer (SCLC) compared to non-small cell lung cancer (NSCLC). The significance of the expression of INSM1 in lung cancer has been largely unknown. We investigated the utility of INSM1 as a novel immunohistochemical marker and researched the biological significance in lung cancer cell lines.
Methods:
We compared INSM1 as an immunohistochemical marker for NE tumours of the lung to conventional markers (chromogranin A (CGA), synaptophysin (SYP), and CD56). To elucidate the biological function of INSM1 in the NE differentiation pathway, we conducted INSM1 gene knockdown/overexpression experiments using human lung cancer cell lines.
Results:
INSM1 was expressed in 100% of SCLCs (44/44), Large cell neuroendocrine cell carcinomas (7/7), and Carcinoids (11/11), but was not expressed in NSCLCs (90 adenocarcinomas and 47 squamous cell carcinomas). This novel immnohistochemical marker showed high sensitivity and specificity when compared to conventional NE markers. We demonstrated that knockdown of INSM1 expression resulted in significant reduction of NE molecules in SCLC cell lines, and overexpression of INSM1 induced NE differentiation in NSCLC cell lines.
Conclusion:
INSM1 was a superior NE immunohistochemical marker when compared to conventional markers. Furthermore, our biological molecular experiments revealed that INSM1 is a critical upstream regulator of the NE differentiation pathway in SCLC cell lines. The elucidation of the significance of INSM1 expression in lung cancer strongly supports the diagnosis of NE tumours of the lung and promotes the understanding of the molecular biology of these tumours.
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
-
+
P1.05 - Poster Session with Presenters Present (ID 457)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Early Stage NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 12/05/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P1.05-039 - Recurrence and Survival Outcome after Segmentectomy for Non-Small Cell Lung Cancer: A Long-Term Follow-Up Study at a Single Institute (ID 5011)
14:30 - 15:45 | Author(s): M. Suzuki
- Abstract
Background:
This study aimed to investigate the factors associated with long-term outcomes of segmentectomy for non-small cell lung cancer (NSCLC) carried out at a single institute.
Methods:
179 patients with stage I NSCLC who underwent a segmentectomy between 2005 and 2009 were investigated. Histological classification was reassessed according to the criteria of the 2015 WHO.
Results:
179 patients with stage I NSCLC (159 adenocarcinomas (ADCs), 14 squamous cell carcinomas (SQCs), 4 adenosquamous carcinomas, and 2 typical carinoids) who underwent segmentectomy between 2005 and 2009 were investigated.The mean follow-up was 73 months. The 5-year overall survival (5-OS) and 5-years disease-free survival (DFS) were 91.8% and 90.2%, respectively. Seven cases of distant recurrence and 8 local-regional recurrence occurred. Multivariate analysis revealed that lymphovascular invasion (LVI) was the independent predictor of 5-OS (P=0.005), and part-solid GGO (GGO ratio < 50%) and LVI were that for 5-DFS (P=0.043, P<0.001). Among invasive ADC patients, micropapillary pattern (MIP) ≧ 5% was identified as an independent predictor of recurrence (P=0.005) and survival (P=0.007). There were five local recurrences in patients with MIP more than 5 years after segmentectomy. Figure 1
Conclusion:
LVI was an independent predictor of the recurrence and overall survival. In patients with invasive ADC, MIP≧5% was a multivariable predictor of recurrence and overall survival. In the patients who underwent a segmentectomy, 5 years without recurrence is not sufficient to conclude that patients with NSCLC is cured.
-
+
P2.08 - Poster Session with Presenters Present (ID 491)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Patient Support and Advocacy Groups
- Presentations: 2
- Moderators:
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.08-007 - Listen Advocate Voice - Web-Survey for the Japanese Model of Lung Cancer Advocacy by Society (ID 5651)
14:30 - 15:45 | Author(s): M. Suzuki
- Abstract
Background:
In Asian countries, the concept of cancer advocacy has not been sufficiently recognized. In Japan, Lung Cancer Society (JLCS) has led the lung cancer advocacy with a part of the NPO, and adopted the 2014 Kyoto Declaration. To evaluate the awareness and attitude of lung cancer advocacy activity among patients, medical workers, and the general population in Japan, web survey was planned for the perceptions of Kyoto declaration and JLCA (Japanese alliance for lung cancer advocacy) events which were carried out by JLCS in these 2 years.
Methods:
An internet survey using survey monkey was conducted which contained 6 closed-ended (selection one or free answers) and open-ended questions, depending on the JLCA network population in June 2016.
Results:
109 people of responded involving 36% of patients and their family, 25% of MD and medical worker, 19% of pharmaceutical company officials and 16% of news media. Perception of Kyoto declaration was 21% of attendee, 27% of well-known, 13% of partial known and 39% of non-awareness. Also the number of participants to the events of JLCA is, 49% of 0 times, 17% 0f 1-2 times, 24% of 3-4 times and 11% of more than 5 times. The most sympathy events ware voted to 1) lecture by a physician 57%, 2) lecture by survivor and the participants WCLC of cancer patients 46%, 3) information in the facebook and the web site 46% 4) citizen open lecture of lung cancer 39%, 5) Performance by society ambassador 38%, 6) advocacy program in annual meetings 26% and 7) Medical seminars around the country 26%. The proportion of respondents who have a certain reputation in the activities of JLCA was 76%. The requests to JLCA is, 1) is the most participation opportunities for information of new treatment and participation opportunities to clinical trial, followed by 2) wish to participate to all the programs in the Society.
Conclusion:
In Japan, awareness about the advocacy is improved, and it was found that the expect to Society for the diverse needs through the Internet survey.
-
+
P2.08-008 - Regional Clinical Pathway for Lung Cancer in Kumamoto University Hospital (ID 4065)
14:30 - 15:45 | Author(s): M. Suzuki
- Abstract
Background:
Although half of people in Japan live in rural districts, cancer centers locate in urban area. Cancer control act was intended to accomplish equal accessibility of cancer medical care across the whole extent of Japan in 2006. According to the act, regional clinical pathways have been started to use. The aim of this study was to evaluate the pathways.
Methods:
Patients with lung cancer who underwent surgery in Kumamoto University Hospital between April 2010 and March 2014 were included. Candidate for the pathway of lung cancer was selected by following criteria. 1) Patient who lives far from our hospital. 2) Patient who eagers to join the pathway. Data were examined retrospectively. Patients usually visit local clinic and undergo examination at our hospital every 6 month. The medical informations are shared with patients, their family and medical staffs with hand-held chart.
Results:
During the study 630 lung cancer patients underwent resection in our hospital. Pathological stages of these patients were, IA in 439, IB in 90, IIA in 37, IIB in 13, IIIA in 71, IIIB in 2, and IV in 15. Of these 681 patients, 67 (11%) entered the regional clinical pathway in our hospital with mean age of 70 ± 10 years old. Pathological stages of the patients who joined regional clinical pathway were, IA in 51 (12%), IB in 8 (9%), IIA in 3 (8%), IIB in 0 (0%), IIIA in 5 (7%), IIIB in 0 (0%), and IV in 0 (0%). Mean observation period was 1083 ± 496 days (62 – 2181). Seven patients died during the study. Ten patients cancelled the pathway. The reasons why the pathway discontinued were as follows: recurrence of lung cancer in 1, other cancer occurrence in 2, patients’ own decision in 4, clinic’s issue in 5. Forty eight patients continue to use the pathway at the end of the study (72%). Mean duration of the pathway the patients used was 993 ± 481 days (3 – 2181). Mean distance between patients’ home and our hospital was 43 ± 34 km (2.6 – 144.5). Because local clinics located closed to patients’ home (mean distance: 12 ± 13 km (0.1 – 55.3)), mean time they spend for attending hospital was reduced from 61 ± 41 minutes (8 – 210) to 19 ± 18 (1 – 83).
Conclusion:
The pathway was used in 72% patients at the end of study and reduced the time patients visiting hospital.
